US 11,851,472 B2
NKG2D-IG fusion protein for cancer immunotherapy
Glenn Dranoff, Sudbury, MA (US); Ryan Sullivan, Watertown, MA (US); and Matthew Vanneman, Cambridge, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc.
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed on Nov. 12, 2020, as Appl. No. 17/096,768.
Application 17/096,768 is a division of application No. 15/775,568, granted, now 10,865,232, issued on Dec. 15, 2020, previously published as PCT/US2016/061479, filed on Nov. 11, 2016.
Claims priority of provisional application 62/255,016, filed on Nov. 13, 2015.
Prior Publication US 2021/0130434 A1, May 6, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); C07K 14/54 (2006.01)
CPC C07K 14/7056 (2013.01) [A61K 38/178 (2013.01); A61K 38/2086 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/70596 (2013.01); C07K 2319/30 (2013.01)] 17 Claims
 
1. A method of treating an NKG2D ligand expressing cancer, comprising administering to a subject in need thereof a polypeptide chain comprising:
(a) a first ligand binding fragment of human NKG2D;
(b) a second ligand binding fragment of human NKG2D; and
(c) an Fc domain of a human immunoglobulin comprising:
(i) a CH2 domain; and
(ii) a CH3 domain.